IL Receptor
抑制剂选择性比较
IL Receptor产品
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| A2011 |
Sarilumab (anti-IL-6Rα)Sarilumab (anti-IL-6Rα)是人源anti-IL-6Rα单克隆抗体，与膜结合的和可溶性的IL-6Rα以高亲和力结合。MW: 144.13 KD。 |
||
| A2012 |
Tocilizumab (anti-IL-6R)Tocilizumab (anti-human IL-6R)是人源单克隆单体，可与interleukin-6 receptor结合发挥抑制作用。MW: 148 KD。 |
||
| S4028 |
Dexamethasone Sodium PhosphateDexamethasone Sodium Phosphate是一种白介素受体抑制剂，抑制COX-2。 |
Dexamethasone and largazole cooperate to suppress invasion and to restore E-cadherin localization to the cell peripher y. ( a) Phase contrast micrographs showing morphological changes in MDA-MB-231 cells induced by E-cadherin expression combined with 100 nM dexamethasone and 10 nM largazole treatments. Insets show the cells at higher magnification. (b ) Fluorescence (E-Cad-GFP) or immunofluorescence microscopy (g -catenin (g-Cat.)) of 231/E-Cad-GFP cells treated for 72 h with vehicle (Control), 100 n M dexamethasone, 10 nM largazole or 100 nM dexamethasone + 10 nM largazole (Dex. + Larg.). (c ) Invasion assays were per formed with the indicated cell lines treated for 72 h with or without 100 nM dexamethasone + 10 nM largazole using modified Boyden chambers impregnated with matrigel. The results are presented as the average number of cells that invaded through the membrane per field s.d. of five randomly chosen fields, and are representative of three independently per formed experiments. |
|
| S2015 |
Suplatast TosylateSuplatast Tosylate是一种Th2细胞因子抑制剂，用作抗过敏剂。 |
||
| S5764 |
YM 90709YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R). |
||
| S4267 |
DiacereinDiacerein抑制促炎细胞因子白细胞介素-1B（IL-1B）产生，用于治疗骨关节炎和慢性炎性关节炎。 |
f, Intra-TG injection of IL-1β inhibitor, Diacerein 10 days after pIONL alleviated pIONL-induced mechanical allodynia from 1 to 6 h. *P < 0.05, ***P < 0.001. Two-way repeated measures ANOVA followed by Bonferroni test. |
|
| S8562 |
CA-4948CA-4948是一种可逆性激酶抑制剂，在TLR和IL-1R信号级联反应中，调节IRAK4的功能。在体内外实验中，具有良好的药代动力学特征和抗肿瘤活性。 |
||
| S8696 |
2-D082-D08是一种具有细胞透性的蛋白类泛素化（protein sumoylation）抑制剂。它还能抑制Axl, IRAK4, ROS1, MLK4, GSK3β, RET, KDR和PI3Kα，IC50分别为0.49, 3.9, 5.3, 9.8, 11, 11, 17和35 nM。 |
||
| S8663 |
TakinibTakinib是一种有效的、选择性的TAK1抑制剂，IC50为9.5 nM。对IRAK4和IRAK1的IC50分别为120 nM和390 nM。 |
||
| S1322 |
DexamethasoneDexamethasone是一种有效的半合成的糖皮质激素类甾体药物，也是一种interleukin receptor调节剂，具有抗炎和免疫抑制作用。 |
Dexamethasone and largazole cooperate to suppress invasion and to restore E-cadherin localization to the cell peripher y. ( a) Phase contrast micrographs showing morphological changes in MDA-MB-231 cells induced by E-cadherin expression combined with 100 nM dexamethasone and 10 nM largazole treatments. Insets show the cells at higher magnification. (b ) Fluorescence (E-Cad-GFP) or immunofluorescence microscopy (g -catenin (g-Cat.)) of 231/E-Cad-GFP cells treated for 72 h with vehicle (Control), 100 n M dexamethasone, 10 nM largazole or 100 nM dexamethasone + 10 nM largazole (Dex. + Larg.). (c ) Invasion assays were per formed with the indicated cell lines treated for 72 h with or without 100 nM dexamethasone + 10 nM largazole using modified Boyden chambers impregnated with matrigel. The results are presented as the average number of cells that invaded through the membrane per field s.d. of five randomly chosen fields, and are representative of three independently per formed experiments. |
|
| S3124 |
Dexamethasone AcetateDexamethasone 是一种有效的糖皮质激素类合成物，属于类固醇药物。Dexamethasone用于很多炎症和自身免疫病的治疗，例如风湿性关节炎和支气管痉挛。接受化疗的癌症病人服用dexamethasone去抵消部分化疗带来的副作用。Dexamethasone 也用在诊断方面，利用它能抑制垂体一肾上腺轴特性。 |
Dexamethasone and largazole cooperate to suppress invasion and to restore E-cadherin localization to the cell peripher y. ( a) Phase contrast micrographs showing morphological changes in MDA-MB-231 cells induced by E-cadherin expression combined with 100 nM dexamethasone and 10 nM largazole treatments. Insets show the cells at higher magnification. (b ) Fluorescence (E-Cad-GFP) or immunofluorescence microscopy (g -catenin (g-Cat.)) of 231/E-Cad-GFP cells treated for 72 h with vehicle (Control), 100 n M dexamethasone, 10 nM largazole or 100 nM dexamethasone + 10 nM largazole (Dex. + Larg.). (c ) Invasion assays were per formed with the indicated cell lines treated for 72 h with or without 100 nM dexamethasone + 10 nM largazole using modified Boyden chambers impregnated with matrigel. The results are presented as the average number of cells that invaded through the membrane per field s.d. of five randomly chosen fields, and are representative of three independently per formed experiments. |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| A2011 |
Sarilumab (anti-IL-6Rα)Sarilumab (anti-IL-6Rα)是人源anti-IL-6Rα单克隆抗体，与膜结合的和可溶性的IL-6Rα以高亲和力结合。MW: 144.13 KD。 |
||
| A2012 |
Tocilizumab (anti-IL-6R)Tocilizumab (anti-human IL-6R)是人源单克隆单体，可与interleukin-6 receptor结合发挥抑制作用。MW: 148 KD。 |
||
| S4028 |
Dexamethasone Sodium PhosphateDexamethasone Sodium Phosphate是一种白介素受体抑制剂，抑制COX-2。 |
Dexamethasone and largazole cooperate to suppress invasion and to restore E-cadherin localization to the cell peripher y. ( a) Phase contrast micrographs showing morphological changes in MDA-MB-231 cells induced by E-cadherin expression combined with 100 nM dexamethasone and 10 nM largazole treatments. Insets show the cells at higher magnification. (b ) Fluorescence (E-Cad-GFP) or immunofluorescence microscopy (g -catenin (g-Cat.)) of 231/E-Cad-GFP cells treated for 72 h with vehicle (Control), 100 n M dexamethasone, 10 nM largazole or 100 nM dexamethasone + 10 nM largazole (Dex. + Larg.). (c ) Invasion assays were per formed with the indicated cell lines treated for 72 h with or without 100 nM dexamethasone + 10 nM largazole using modified Boyden chambers impregnated with matrigel. The results are presented as the average number of cells that invaded through the membrane per field s.d. of five randomly chosen fields, and are representative of three independently per formed experiments. |
|
| S2015 |
Suplatast TosylateSuplatast Tosylate是一种Th2细胞因子抑制剂，用作抗过敏剂。 |
||
| S5764 |
YM 90709YM 90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R). |
||
| S4267 |
DiacereinDiacerein抑制促炎细胞因子白细胞介素-1B（IL-1B）产生，用于治疗骨关节炎和慢性炎性关节炎。 |
f, Intra-TG injection of IL-1β inhibitor, Diacerein 10 days after pIONL alleviated pIONL-induced mechanical allodynia from 1 to 6 h. *P < 0.05, ***P < 0.001. Two-way repeated measures ANOVA followed by Bonferroni test. |
|
| S8562 |
CA-4948CA-4948是一种可逆性激酶抑制剂，在TLR和IL-1R信号级联反应中，调节IRAK4的功能。在体内外实验中，具有良好的药代动力学特征和抗肿瘤活性。 |
||
| S8696 |
2-D082-D08是一种具有细胞透性的蛋白类泛素化（protein sumoylation）抑制剂。它还能抑制Axl, IRAK4, ROS1, MLK4, GSK3β, RET, KDR和PI3Kα，IC50分别为0.49, 3.9, 5.3, 9.8, 11, 11, 17和35 nM。 |
||
| S8663 |
TakinibTakinib是一种有效的、选择性的TAK1抑制剂，IC50为9.5 nM。对IRAK4和IRAK1的IC50分别为120 nM和390 nM。 |
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1322 |
DexamethasoneDexamethasone是一种有效的半合成的糖皮质激素类甾体药物，也是一种interleukin receptor调节剂，具有抗炎和免疫抑制作用。 |
Dexamethasone and largazole cooperate to suppress invasion and to restore E-cadherin localization to the cell peripher y. ( a) Phase contrast micrographs showing morphological changes in MDA-MB-231 cells induced by E-cadherin expression combined with 100 nM dexamethasone and 10 nM largazole treatments. Insets show the cells at higher magnification. (b ) Fluorescence (E-Cad-GFP) or immunofluorescence microscopy (g -catenin (g-Cat.)) of 231/E-Cad-GFP cells treated for 72 h with vehicle (Control), 100 n M dexamethasone, 10 nM largazole or 100 nM dexamethasone + 10 nM largazole (Dex. + Larg.). (c ) Invasion assays were per formed with the indicated cell lines treated for 72 h with or without 100 nM dexamethasone + 10 nM largazole using modified Boyden chambers impregnated with matrigel. The results are presented as the average number of cells that invaded through the membrane per field s.d. of five randomly chosen fields, and are representative of three independently per formed experiments. |
|
| S3124 |
Dexamethasone AcetateDexamethasone 是一种有效的糖皮质激素类合成物，属于类固醇药物。Dexamethasone用于很多炎症和自身免疫病的治疗，例如风湿性关节炎和支气管痉挛。接受化疗的癌症病人服用dexamethasone去抵消部分化疗带来的副作用。Dexamethasone 也用在诊断方面，利用它能抑制垂体一肾上腺轴特性。 |
Dexamethasone and largazole cooperate to suppress invasion and to restore E-cadherin localization to the cell peripher y. ( a) Phase contrast micrographs showing morphological changes in MDA-MB-231 cells induced by E-cadherin expression combined with 100 nM dexamethasone and 10 nM largazole treatments. Insets show the cells at higher magnification. (b ) Fluorescence (E-Cad-GFP) or immunofluorescence microscopy (g -catenin (g-Cat.)) of 231/E-Cad-GFP cells treated for 72 h with vehicle (Control), 100 n M dexamethasone, 10 nM largazole or 100 nM dexamethasone + 10 nM largazole (Dex. + Larg.). (c ) Invasion assays were per formed with the indicated cell lines treated for 72 h with or without 100 nM dexamethasone + 10 nM largazole using modified Boyden chambers impregnated with matrigel. The results are presented as the average number of cells that invaded through the membrane per field s.d. of five randomly chosen fields, and are representative of three independently per formed experiments. |
沪公网安备 31011502012800号